论文部分内容阅读
70例口服降糖药(OAD)但血糖控制不良的(T2DM)患者(HbA1c>7.5%),随机分为Glargine治疗组(n=35)和NPH组(n=35),分别采用每晚10点注射Glargine和NPH加口服格华止500mg,tid治疗。根据空腹血糖(FBG)调整用量,以达到5.6mmol/L为治疗目标,共12周,结果:平均FBG和HbA1c无明显差异(P>0.05);但Glargine组低血糖发生率明显少于NPH组(P<0.05)。结论:每日注射1次长、中效胰岛素联合格华止的方案可使血糖控制不良的T2DM患者血糖获得理想控制,Glargine的低血糖发生率明显低于NPH。
(HbA1c> 7.5%) in 70 patients with oral hypoglycemic agents (OAD) and poor glycemic control (T2DM) were randomly divided into Glargine treatment group (n = 35) and NPH group (n = 35) Point injection Glargine and NPH plus oral Gefitinan 500mg, tid treatment. According to the adjustment of fasting blood glucose (FBG) dosage, the therapeutic target of 5.6 mmol / L was achieved for 12 weeks. There was no significant difference between the average FBG and HbA1c (P> 0.05); however, the incidence of hypoglycemia in Glargine group was significantly lower than that in NPH group (P <0.05). CONCLUSIONS: One-day injections of long-acting and medium-acting insulin combined with Grifar are ideal for control of blood glucose in T2DM patients with poor glycemic control. The incidence of hypoglycemia in Glargine is significantly lower than that of NPH.